INBRIJA

This brand name is authorized in Austria, Estonia, Ireland, Lithuania, Poland, United States

Active ingredients

The drug INBRIJA contains one active pharmaceutical ingredient (API):

1 Levodopa
UNII 46627O600J - LEVODOPA

According to the current understanding, the symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease.

Read about Levodopa

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
INBRIJA Inhalation powder, capsule FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N04BA01 Levodopa N Nervous system → N04 Anti-parkinson drugs → N04B Dopaminergic agents → N04BA Dopa and dopa derivatives
Discover more medicines within N04BA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1802247, 1802258
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1088511, 1088512
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100424346
Country: US FDA, National Drug Code Identifier(s): 10144-342

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.